EILEAN THERAPEUTICS APPROVED TO INITIATE FIRST PATIENT TRIAL WITH BALAMENIB (ZE63-0302), A SELECTIVE BEST-IN-CLASS MENIN INHIBITOR ...Middle East

DOVER, Del., March 11, 2024 /PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, today announced that Eilean...

Hence then, the article about eilean therapeutics approved to initiate first patient trial with balamenib ze63 0302 a selective best in class menin inhibitor was published today ( Monday 11/03/2024 - 07:52 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( EILEAN THERAPEUTICS APPROVED TO INITIATE FIRST PATIENT TRIAL WITH BALAMENIB (ZE63-0302), A SELECTIVE BEST-IN-CLASS MENIN INHIBITOR )

Also on site :

• The Newest 'Fun Ship' in the World Just Picked a Surprising U.S. Homeport
• Ann-Margret Is About to Turn 85—Her Birthday Plans Might Surprise You (Exclusive)
• Most Australian teens admit the social media ban isn’t working as they try to sidestep age verification blocks with face masks and their parents’ IDs